Highlight
• Finerenone significantly reduces the risk of cardiovascular death and total worsening heart failure (HF) events in patients with HFmrEF and HFpEF.
• This benefit is consistent across frailty classes, including the most frail patients.
• Frailty status does not modify the safety profile of finerenone regarding hypotension, renal function, or electrolyte disturbances.
• Clinicians should consider finerenone therapy irrespective of patients’ frailty levels to optimize HF outcomes.
